Key findings include: Unprecedented HbA1c reductions ranging from 1.9% to 2.6% across different trials and populations SURPASS-1 (monotherapy): Up to 92% of participants achieved HbA1c less than 7%, with 52% reaching normoglycemia (HbA1c less than 5.7%) SURPASS-2 (versus semaglutide 1 mg): GLP2 demonstrated superior HbA1c and weight reduction at all doses compared to the leading GLP-1 receptor agonist SURPASS-3 (versus insulin degludec): Superior glycemic control when added to metformin with or without SGLT2 inhibitors SURPASS-4 (versus insulin glargine): Improved outcomes in patients with elevated cardiovascular risk Across all SURPASS trials, GLP2 showed consistent efficacy with low rates of clinically significant hypoglycemia (blood glucose less than 54 mg/dL)
Healthy fats Healthy fats, like avocados, nuts, seeds, olive oil, and fatty fish like salmon can boost GLP-1 secretion
These findings suggest that the microbiome may contribute to the pathogenesis of depression through complex interactions involving microbial metabolites, neurotransmitter regulation, and immune system modulation
This finding suggests that the anti-oxidative stress effect of NAC may affect the cleavage of APP protein post-transcriptionally
Read full insight Related Reading Most people searching l-carnitine for dogs arent chasing a biochemical concepttheyre chasing reassurance